17.02.2020 • News

New Shintec Cracker up and running on US Gulf

New Shintec Cracker up and running on US Gulf (c) Shintec
New Shintec Cracker up and running on US Gulf (c) Shintec

Shintech, US subsidiary of Japanese PVC producer Shin-Etsu Chemical – the world’s largest player – has finally started up its long planned 500,000 t/y ethane cracker at its site in Plaquemine, Louisiana, USA, near Baton Rouge.

Start-up of the facility, which will take advantage of the abundant shale gas reserves in the US Gulf region, was announced by Toyo, the Japanese contractor that handled engineering, procurement and construction (EPC) for the project.

Lummus Technology US provided the ethylene process technologies for the cracker, which will supply captive feedstock to the site’s planned VCM and PVC production, further back-integrating the site’s infrastructure

The US cracker was initially expected to go on stream in 2018, but was delayed without comment. Commissioning has been in progress for nearly a year, according to reports that have emerged in dribbles.

Two years ago, Shintec also announced it would also build plants to produce 860,000 t/y of VCM and 660,000 t/y of caustic soda at the Louisiana complex. The first phase, to cost $1.49 billion, is would increase capacity for PVC by 290,000 t/y and for caustic soda by 270,000t/y, lifting the US company’s total capacity to 3.24 million t/y and 1.57 million t/y, respectively.

At the time, construction of the downstream facilities was expected to be completed by the end of 2020. Shintec has not announced any further details of the project’s progress.


 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read